Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Idraparinux sodium for prevention of stroke in patients with atrial fibrillation - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2004
Authors' objectives
This study aims to summarise the currently available evidence on idraparinux sodium for prevention of stroke in patients with atrial fibrillation.
Authors' conclusions
Idraparinux sodium (SanOrg-34006) is a long-acting antithrombotic agent in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF). It is a methylated derivative of the synthetic pentasaccharide fondaparinux, and is administered as a once weekly subcutaneous injection. It is not clear at this stage if idraparinux is intended for all patients with AF, or for patients with AF and one or more other risk factors for stroke. Idraparinux is also in phase III clinical trials for the treatment and long-term secondary prevention of venous thromboembolism (VTE).
Anticoagulants; Atrial Fibrillation; Stroke /prevention& control
Language Published
English
Country of organisation
England
English summary
An English language summary is available.
Address for correspondence
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk